Summary
The product AAS capsule OX, manufactured by Mintanabolics, underwent independent testing to verify its composition and potency. The sample was submitted by Mintanabolics and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the concentration of Oxandrolone at 5.88 mg, 6.32 mg, and 5.43 mg in three tested samples.
The testing process began on 2 May 2024, with the sample received on 26 June 2024, and analysis completed on 28 June 2024. While the results confirm the composition of the product, independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Mintanabolics
- Product Name: AAS capsule OX
- Active Ingredient: Oxandrolone
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #44531
- Testing Ordered: 2 May 2024
- Sample Received: 26 June 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Mintanabolics (Manufacturer)
- Analysis Paid For By: Mintanabolics (Manufacturer)
Testing Results
- Oxandrolone Concentrations:
- Sample 1: 5.88 mg
- Sample 2: 6.32 mg
- Sample 3: 5.43 mg
Verification Details
Verification URL: https://janoshik.com/tests/44531_C5VK9MPQT3L9
Evaluation of Manufacturer-Submitted Testing
This analysis provides transparency regarding the product’s composition but also raises the need for external validation. Since Mintanabolics submitted and funded the test, independent verification through third-party testing across multiple batches would be beneficial. While Janoshik Analytical is recognized for its rigorous protocols, further scrutiny is encouraged to ensure product consistency.
Conclusion
The analysis confirms that AAS capsule OX contains Oxandrolone with concentrations of 5.88 mg, 6.32 mg, and 5.43 mg across three tested samples. While the product appears to align with expected formulations, continued testing is essential to verify consistency across batches. This report aims to support educational and harm reduction efforts, assisting consumers in making informed decisions regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it still provides useful data when critically assessed alongside third-party results. Readers are encouraged to use this information responsibly.
